+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Sacubitril"

Global Cardiovascular Drugs Market by Drug Type (Angiotensin Inhibitors, Anticoagulants, Antihyperlipidemic), Disease Indication (Arrhythmia, Coronary Artery Disease, Hyperlipidaemia), Route of Administration, Mode of Purchase, End-Users - Forecast 2024-2030 - Product Thumbnail Image

Global Cardiovascular Drugs Market by Drug Type (Angiotensin Inhibitors, Anticoagulants, Antihyperlipidemic), Disease Indication (Arrhythmia, Coronary Artery Disease, Hyperlipidaemia), Route of Administration, Mode of Purchase, End-Users - Forecast 2024-2030

  • Report
  • May 2024
  • 185 Pages
  • Global
From
Angiotensin Receptor Blockers (ARBs) Global Market Report 2024 - Product Thumbnail Image

Angiotensin Receptor Blockers (ARBs) Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Global Dilated Cardiomyopathy Market by Drug Class Inhibitors, Treatment Type, Route of Administration, Distribution Channel, and By Region - Product Thumbnail Image

Global Dilated Cardiomyopathy Market by Drug Class Inhibitors, Treatment Type, Route of Administration, Distribution Channel, and By Region

  • Report
  • March 2024
  • 200 Pages
  • Global
From
Congestive Heart Failure (CHF) - Market Insights, Epidemiology, and Market Forecast-2032 - Product Thumbnail Image

Congestive Heart Failure (CHF) - Market Insights, Epidemiology, and Market Forecast-2032

  • Report
  • February 2022
  • 220 Pages
  • Global
From
Cardiomyopathies Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 - Product Thumbnail Image

Cardiomyopathies Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

  • Drug Pipelines
  • June 2022
  • 101 Pages
  • Global
From
Hypertrophic Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Hypertrophic Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 87 Pages
  • Global
From
  • 6 Results (Page 1 of 1)
Loading Indicator

Sacubitril is a cardiovascular drug used to treat heart failure. It is a neprilysin inhibitor, meaning it works by blocking the action of an enzyme that breaks down certain hormones in the body, allowing them to remain active and help the heart pump more efficiently. Sacubitril is usually prescribed in combination with another drug, valsartan, to reduce the risk of hospitalization and death due to heart failure. It is available in tablet form and is taken twice daily. Sacubitril is a relatively new drug, having been approved by the US Food and Drug Administration in 2015. It has been shown to be effective in reducing the risk of hospitalization and death due to heart failure, and is generally well-tolerated. The Sacubitril market is highly competitive, with several major pharmaceutical companies offering the drug. These include Novartis, AstraZeneca, and Mylan. Other companies, such as Teva Pharmaceuticals and Sandoz, also offer generic versions of the drug. Show Less Read more